Key Stats for HIMS Stock
- Past week’s performance: -6.7%
- 52-week range: $14 to $70
- Valuation model target price: $32
- Implied upside: 17.7% over 2.7 years
Value your favorite stocks like HIMS with 5 years of analysts’ forecasts using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Hims & Hers Health, Inc. (HIMS) fell about 6.7% this week as the FDA proposed new curbs on mass compounding of branded weight-loss drugs. Compounded medications are lower-cost alternatives to FDA-approved drugs, mixed and distributed by specialty pharmacies outside the standard manufacturing process.
Hims & Hers built a fast-growing business offering compounded semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, to patients at roughly $49 per month. So the FDA’s proposal directly threatens one of the company’s most important and highest-growth revenue categories.
The regulatory environment for HIMS had already been difficult in early 2026. In February, the Department of Health and Human Services referred Hims to the DOJ for potential violations related to its compounding practices.
HIMS said it looked forward to engaging with the FDA on safe access to affordable healthcare. And yet, in March, Novo Nordisk’s FDA-approved GLP-1 drugs became available directly through the Hims platform, representing a pivot toward branded medications.
On the positive side, JPMorgan initiated coverage with an overweight rating in late April, and the stock rose earlier in the month on FDA news about potential broader access to peptides. Hims also expanded into menopause care, tapping into demand for estrogen patches amid US supply shortages.
HIMS nominated Kofi Amoo-Gottfried, a seasoned marketing executive, to its board of directors. These moves signal that Hims is actively diversifying beyond GLP-1s and building a broader women’s health platform.
Q4 2025 revenue came in at $617.8 million, slightly below the $619.2 million estimate, but the full strategic picture includes the $1.15 billion acquisition of Australian telehealth company Eucalyptus announced in February.
Going forward, investors will watch how the FDA’s proposed compounding rules affect revenue guidance and how quickly the Eucalyptus deal contributes to growth.
See analysts’ growth forecasts and price targets for HIMS (It’s free) >>>
Is HIMS Stock Undervalued?
Under valuation model assumptions realized through 12/31/28, the stock is modeled using:
- Revenue growth (CAGR): 15.9%
- Operating Margins: 4.5%
- Exit P/E Multiple: 24.7x
Based on these inputs, the model estimates a target price of $33, implying 17.7% total upside from the current share price of $28 and a 6.3% annualized return over the next 2.7 years.
The model implies a 6.3% annualized return, which falls below the 10% threshold typically associated with attractive long-term investments. The street consensus target of $26.25 is actually below the current share price of $27, suggesting the average analyst views HIMS as slightly overvalued today.
But the gap between JPMorgan’s overweight thesis and the consensus target reflects deep uncertainty about the regulatory path for the company.
Revenue grew an extraordinary 59% in the past year, driven heavily by GLP-1 weight-loss subscriptions. But the 15.9% forward CAGR assumption reflects a meaningful slowdown as regulation tightens and competition intensifies.
Branded GLP-1s through the Hims platform could offset some lost compounding revenue, but at much lower margins than proprietary compounded formulas. And so the revenue mix shift, if it happens, would likely put downward pressure on the operating margin too.
The 4.5% operating margin assumption is thin and reflects continued heavy spending on marketing, customer acquisition, and platform expansion. The current LTM EBIT margin sits at 5.2%, so the model assumes a slight margin contraction from current levels.
Because regulatory risk is elevated and the business is still in an investment phase, the model points to a below-average return scenario. A more bullish case on growth or margins would be needed to justify a meaningfully higher target.
What’s Driving HIMS Stock Going Forward?
The FDA’s proposed rules on mass compounding of GLP-1 drugs are the single biggest near-term catalyst for HIMS. If regulators restrict compounding, Hims would need to accelerate its shift to branded Novo Nordisk and Eli Lilly medications.
That shift would likely reduce revenue per patient, since branded drugs carry lower platform margins than proprietary compounded formulas. And so the timeline and scope of any FDA ruling will dominate HIMS stock performance in the months ahead.
The Eucalyptus acquisition is the most important strategic move Hims has made in the past year. Eucalyptus is an Australian telehealth platform serving patients across multiple health conditions. The deal is valued at up to $1.15 billion and brings Hims new customers, new geography, and new clinical capabilities. But the integration success and revenue contribution timeline are not yet clear to investors.
Women’s health is an emerging and high-potential growth category for Hims. The company’s expansion into menopause care and estrogen patches addresses a large and underserved patient population.
Hims already has strong brand recognition among women through hair and skin care products, so the cross-sell opportunity is meaningful. If women’s health revenue grows to a significant share of total revenue, it could help offset near-term GLP-1 headwinds.
Finally, the broader telehealth market continues to expand as consumers embrace digital-first healthcare access. Hims & Hers has a strong brand and a high-growth subscriber model, but regulatory risk and margin pressure are real challenges.
Management’s navigation of the FDA’s evolving stance on compounding will be the defining investor question throughout 2026. If Hims can preserve GLP-1 access while building new specialties, the long-term thesis could remain credible despite the near-term turbulence.
Estimate a company’s fair value instantly (Free with TIKR) >>>
Should You Invest in Hims & Hers?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up HIMS, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track HIMS alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Hims & Hers stock on TIKR Free→
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
